PURE BIOSCIENCE, INC. (PURE): Results of Operations and Financial Condition
PURE BIOSCIENCE, INC. (PURE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 PURE Bioscience Reports Fiscal Third Quarter 2026 Financial Results EL CAJON, Calif. – PURE Bioscience, Inc. ( OTCQB: PURE ) (“PURE,” the “Company” or “we”), creator of the patented non-toxic silver dihydrogen citrate ( SDC ) antimicrobia
How this was made
The 30-second read
Why it matters
Traders can reassess near-term fundamentals using the disclosed quarterly and year-to-date sales/loss figures, and reprice governance/execution risk ahead of the CEO handoff on Aug 1, 2026.
Market read
Primary-source financials plus a defined CEO transition date can drive microcap sentiment and positioning, even without explicit guidance.
What to watch
Investors may focus more on the CEO transition mechanics and board changes than on the quarterly P&L, especially in a thinly traded OTCQB name.
Background
This is a Form 8-K (Item 2.02) with Exhibit 99.1 reporting PURE Bioscience’s fiscal third-quarter results and providing business/management updates.
Ticker impact
PURE reported fiscal Q3 ended April 30, 2026 results, including net product sales of $506k and a net loss of $624k, plus CEO succession.
Likely modest volatility around microcap liquidity as traders digest losses, sales growth, and management change; direction depends on whether investors view PURE Clean adoption and cost reductions as durable.
The filing is a primary SEC 8-K with concrete P&L figures and specific governance timeline, but it does not provide guidance or a clear inflection point beyond qualitative adoption updates.
Market effects
Microcap antimicrobial/food-safety platform companies may see read-across interest if PURE Clean adoption and distribution penetration are viewed as validating the SDC platform.
Limited; company is US-based and updates are company-specific.
Low; no international regulatory or supply-chain shocks disclosed.
Counterpoint
Sales growth is small in absolute terms ($506k vs $489k), while losses remain sizable, so the market may discount the adoption narrative until revenue scales materially.
Key entities
- companyPURE Bioscience, Inc.
OTCQB-listed antimicrobial technology company reporting fiscal Q3 results and CEO succession.
- personRobert Bartlett
Announced plans to retire as CEO effective July 31, 2026; remains Board Member and Advisor.
- personJeff Kitchell
Appointed to take over as CEO effective August 1, 2026; also becomes Board Member.
- personBernard Blotner
Leaving PURE’s Board of Directors.
